SecBot SecBot
SECBOTREPLAY Home › Report › INKT

INKT · MiNK Therapeutics presented data at ASGCT 2026 showing its…

MiNK Therapeutics · PRESS-RELEASE filed May 12, 2026 at 07:35 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed May 12, 2026 at 07:35 ET

MiNK Therapeutics presented data at ASGCT 2026 showing its off-the-shelf iNKT cell therapy, agenT-797, produced context-dependent immune responses (pro-inflammatory in cancer, anti-inflammatory in ARDS) from the same manufacturing batch without genetic engineering. The data supports advancement into a randomized Phase 2 trial in acute lung injury, with preliminary results expected in 2026.

  • agenT-797 drove TH1 pro-inflammatory immune program in 34 solid tumor patients and TH2 anti-inflammatory response in 20 ARDS patients from the same donor batch.
  • Data includes complete metastatic remission in germ cell testicular cancer (agenT-797 + anti-PD-1) and improved survival/pathogen clearance in severe ARDS.
  • Favorable safety profile: no uncontrolled cytokine release syndrome or pathologic hyperinflammation.
  • Company advancing to randomized Phase 2 trial in acute lung injury (C-1300-02) with preliminary data expected in 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access